Create infrastructure/resources for extensive characterization of existing and new animal models and development of standardized and rigorous methods for preclinical efficacy testing including web-based resources for transparent reporting of both positive and negative findings.
- Create at least one translational center for animal model resources.
- Support the generation of large longitudinal, multi-omic data on existing and newly developed transgenic mouse models necessary to build “molecular network maps” that connect molecular attributes of AD across mouse models and humans.
- Enable comprehensive analyses of ‘clinical’ and deep omics profiles in panels of genetically diverse mice, to better model human genomes.
- Create a publicly available database that houses experimental designs and analysis relating to the preclinical testing of candidate therapeutics in AD animal models. The data base should function as a knowledge platform for data sharing, mining and analysis and should help identify critical experimental design elements and methodology that impact the rigor and reproducibility of published studies.
- Research Implementation Area
- Translational Tools, Infrastructure and Capabilities
Research Programs and Resources
- Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD)
- MODEL-AD Translational Center for Model Development and Evaluation for Late Onset
- MODEL-AD Resources
- STOP-AD Compound Submission Portal
- AlzPED Alzheimer’s Disease Preclinical Efficacy Database (AlzPED)